For too long, doctors treating rheumatic diseases have had to base their management on instinct and experience.
The problem is that each physician has a limited experience – which means that many times we basically had to guess at how to treat a specific patient, using trial and error to find out what might work best.
This study shows that well-validated symptom surveys could be used by doctors to identify suggestive symptom patterns that could lead to the diagnosis of PTLDS.
An antibody biomarker was recently discovered that identifies people with chronic skeletal muscle disease and severe heart muscle involvement.
A survey of more than 600 people with myositis from the US, Korea, and Sweden identified 5 aspects of living with the disease that are most important to patients.
A new study found that people with scleroderma who have muscle weakness due to the accumulation of fibrous tissue in their muscles, are at risk for severe disease outcomes including death from heart disease.
A collaborative effort between Rheumatology and Oncology offers guidance to doctors treating patients for inflammatory arthritis caused by treatment with “immune checkpoint inhibitors”, a type of cancer therapy.
